ArticleJAMA network open2023
Evaluation of Out-of-Pocket Costs and Treatment Intensification With an SGLT2 Inhibitor or GLP-1 RA in Patients With Type 2 Diabetes and Cardiovascular Disease.
Jing Luo et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
43 papers cite it
this papertrialcites it